Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Markus Peters, former chief operating officer of Gemini Therapeutics, takes the helm of Aevitas Therapeutics as its newest CEO.
Deborah Geraghty has been named president and CEO of Swiss biotech company Anokion. Most recently, Geraghty was Anokion’s chief operating officer.
Moncef Slaoui has been tapped to serve as chief scientific officer of Centessa Pharmaceuticals. Slaoui recently resigned from his chief scientific adviser post with the U.S. COVID-19 vaccine effort Operation Warp Speed.
Cue Biopharma has named Matteo Levisetti senior vice president of clinical development. Levisetti was formerly the chief medical officer of DNAtrix.
Daiichi Sankyo has appointed Ken Takeshita as the company’s global head of R&D. Takeshita previously served as senior vice president and global head of development at Kite Pharma.
Tahamtan Ahmadi has been appointed to the newly created role of chief medical officer and head of experimental medicines at Genmab. Ahmadi was previously Janssen’s head of experimental medicine and early development oncology divisions.
Eric Feldman has been promoted from vice president of global clinical development to chief medical officer of GlycoMimetics. Prior to joining GlycoMimetics, Feldman was chief medical officer at Amphivena Therapeutics.
Ren Feng has been hired by Insilico Medicine to serve as the company’s chief scientific officer. Most recently, Feng was senior vice president at Medicilon.
Laura Kelly has been appointed director of clinical operations at Monopar Therapeutics. Prior to this appointment, Kelly served as senior manager and clinical site lead at EMD Serono.
Amit Nathwani, founder of NovalGen, is now CEO of the company. Nathwani, who is a professor of immunology at University College London, previously served as chief scientific officer of Freeline Therapeutics.
OncoSec has named Bridget O’Keeffe vice president of clinical development. O’Keeffe was most recently senior director of clinical development for Nektar Therapeutics.
Glenn Noronha, former chief scientific officer at BridgeBio, has been named chief development officer of PYC Therapeutics.
Biotech company Wugen has appointed Jan Davidson to the role of chief medical officer. Davidson was most recently senior director for clinical research at Macrogenics.
Vafa Jamali has signed on as the CEO of Zimmer Biomet’s new spine and dental spinout business NEWCO. Jamali was recently the chief commercial officer for Rockley Photonics.